BiotechTube
Sound Biologics

Sound Biologics

Seattle, United States· Est.
soundbiologics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Sound Biologics is a clinical-stage biotech leveraging its proprietary MabPair and Bispecific platforms to create novel antibody combination therapies. The company's lead immuno-oncology program has reached patients in China, with additional programs advancing in inflammation and neurology. Sound Biologics aims to improve therapeutic efficacy and accessibility by streamlining combination treatments into single, manufacturable drug products.

OncologyAutoimmune DiseasesInflammatory DiseasesNeurology

Technology Platform

Proprietary MabPair platform for co-expression of two distinct monoclonal antibodies from a single cell line, and a complementary Bispecific platform for stable heterodimeric antibodies.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The growing validation of combination therapies in oncology and autoimmune diseases creates a significant market for streamlined, single-product combinations.
Sound Biologics' MabPair technology offers a potentially more manufacturable and cost-effective solution than traditional antibody cocktails, positioning it well for partnerships and addressing payer concerns over high drug costs.

Risk Factors

Key risks include clinical failure of the lead MabPair program, which would challenge the platform's validity, and intense competition from large biopharma and other biotechs in the bispecific/combination therapy space.
As a private, pre-revenue company, it also faces ongoing financial risk and dependency on fundraising.

Competitive Landscape

Sound Biologics competes in the crowded arena of multi-specific antibodies and combination therapies. It differentiates itself with the MabPair approach, which aims for the flexibility of a cocktail with the manufacturing simplicity of a single product. Major competitors include large biopharma with extensive bispecific pipelines (e.g., Roche, Amgen) and numerous platform biotechs focused on antibody engineering.

More companies in Biologics / Biosimilars →More companies in United States →